Aktienanalyse zu Pfizer Inc (PFE)PFEPfizer Inc

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pfizer Inc is a good buy right now due to its current price of $28.28, which is below the analyst price target of $30, indicating a potential upside of approximately 6.1%. Additionally, the forward P/E ratio of 9.67 suggests that the stock is undervalued compared to its earnings potential. However, the company faces risks, including a recent job cut announcement affecting 330 positions, which could impact morale and operations.

22 analysts cover PFE: 12 rate it Buy, 9 Hold and 1 Sell. The average price target is 28.56.